Fate Therapeutics, Inc. , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today reported therapeutic program updates and announced financial results for the fourth quarter and year ended December 31, 2013.
http://ift.tt/PJrtWc
http://ift.tt/PJrtWc
No comments:
Post a Comment